Evidence map›Paper›PMID 37033983›Full record

ArticleFrontiers in immunology2023

Convergent antibody responses are associated with broad neutralization of hepatitis C virus.

Nicole E Skinner, Clinton O Ogega, Nicole Frumento, Kaitlyn E Clark, Srinivasan Yegnasubramanian, Kornel Schuebel, Jennifer Meyers, Anuj Gupta, Sarah Wheelan, Andrea L Cox and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Nicole E SkinnerCenter for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, United States.
Clinton O OgegaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Nicole FrumentoDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Kaitlyn E ClarkDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Srinivasan YegnasubramanianDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Kornel SchuebelDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Jennifer MeyersDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Anuj GuptaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Sarah WheelanDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Andrea L CoxDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
Stuart C RayDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Justin R BaileyDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Johns Hopkins University · USNationwide Children's Hospital · USVanderbilt University Medical Center · US

Funding

The development and pre-clinical assessment of novel HCV vaccines to generate T and B cell immunityU19AI159822 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2021 to 2025
$14.4M
Molecular and structural characterization of broadly neutralizing anti-HCV antibodiesR01AI127469 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Justin Richard Bailey · 2017 to 2026
$6.8M
Development of a single-cell antibody cloning protocol for isolation of hepatitis C virus-specific broadly neutralizing antibodiesR21AI151353 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BAILEY, JUSTIN RICHARD · 2020 to 2021
$450k
NIAID NIH HHS R01 AI127469NIAID NIH HHS R21 AI151353NIAID NIH HHS U19 AI159822
6 · The paper itself

Abstract

Introduction: Early development of broadly neutralizing antibodies (bNAbs) targeting the hepatitis C virus (HCV) envelope glycoprotein E2 is associated with spontaneous clearance of infection, so induction of bNAbs is a major goal of HCV vaccine development. However, the molecular antibody features important for broad neutralization are not known. Methods: To identify B cell repertoire features associated with broad neutralization, we performed RNA sequencing of the B cell receptors (BCRs) of HCV E2-reactive B cells of HCV-infected individuals with either high or low plasma neutralizing breadth. We then produced a monoclonal antibody (mAb) expressed by pairing the most abundant heavy and light chains from public clonotypes identified among clearance, high neutralization subjects. Results: We found distinctive BCR features associated with broad neutralization of HCV, including long heavy chain complementarity determining region 3 (CDRH3) regions, specific VH gene usage, increased frequencies of somatic hypermutation, and particular VH gene mutations. Most intriguing, we identified many E2-reactive public BCR clonotypes (heavy and light chain clones with the same V and J-genes and identical CDR3 sequences) present only in subjects who produced highly neutralizing plasma. The majority of these public clonotypes were shared by two subjects who cleared infection. A mAb expressing the most abundant public heavy and light chains from these clearance, high neutralization subjects had features enriched in high neutralization clonotypes, such as increased somatic hypermutation frequency and usage of Discussion: Together, these results demonstrate distinct BCR repertoires associated with high plasma neutralizing capacity. Further characterization of the molecular features and function of these antibodies can inform HCV vaccine development.

Indexed as

HepacivirusHepatitis CAntibodies, MonoclonalAntibodies, NeutralizingAntibody FormationBroadly Neutralizing AntibodiesComplementarity Determining RegionsHumansAntibodies, MonoclonalAntibodies, NeutralizingBroadly Neutralizing AntibodiesComplementarity Determining RegionsB cellB cell receptorhepatitis C virusneutralizing antibodyvaccine

Identifiers

PMID37033983
PMCPMC10080129
OpenAlexW4360866194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.